About Elypta
Elypta is developing the first-ever metabolism-based liquid biopsy platform for early detection and closer follow-up of multiple cancer indications. The platform is inherently safe and convenient, exceptionally sensitive in studies to date and the low cost assay technology allows for broad use. Furthermore, the score output is customizable with early results suggesting correlation with the severity of disease. These features enable multiple potential applications, currently explored in the lead indication renal cell carcinoma:
1. Detection of early stage cancer when symptoms are inconclusive.
2. Earlier detection of recurring cancer by safer, more convenient and closer surveillance post-surgery.
3. Guide therapy by safer, more convenient and closer monitoring of response to treatment.
- Founding: 2017
- Focus : Manufacturer
- Employees: 1-10
- Industry : Diagnostics
Product portfolio of Elypta
Here you will find Elypta AB
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
